Effect of 4 years subcutaneous insulin infusion treatment on albuminuria, kidney function and HbA1c compared with multiple daily injections: a longitudinal follow‐up study
- 2 September 2015
- journal article
- research article
- Published by Wiley in Diabetic Medicine
- Vol. 32 (11), 1445-1452
- https://doi.org/10.1111/dme.12950
Abstract
Aim The effect of insulin pump [continuous subcutaneous insulin infusion (CSII)] treatment on diabetes complications in a modern clinical setting is largely unknown. We investigated the effect of 4 years CSII treatment on HbA1c, albuminuria and kidney function compared with multiple daily injections (MDI) in a single‐centre clinical setting. Methods All patients initiating CSII treatment from 2004 to 2010 and followed for at least 4 years were included in the study: 193 people with Type 1 diabetes were matched (1 : 2) with 386 patients treated with MDI in the same period. Matching was based on diabetes duration, gender, HbA1c and normo‐, micro‐ or macroalbuminuria at baseline. Urinary albumin/creatinine ratio (UACR) was measured yearly and annual change assessed from linear regression. Results CSII‐ vs. MDI‐treated patients were comparable at baseline. After 4 years, HbA1c was 62 ± 11 vs. 68 ± 11 mmol/mol (7.8 ± 1.0 vs. 8.4 ± 1.0%) (P < 0.001). Annual UACR change in CSII‐ vs. MDI‐treated patients was [mean (95% confidence interval)] −10.1 (−13.3; −6.8) vs. −1.2 (−3.6; 0.9)% (P < 0.001). Reduction in UACR was significantly associated with CSII treatment after adjustment for age, gender, diabetes duration, estimated GFR, UACR, mean arterial pressure, HbA1c, cholesterol, renin–angiotensin–aldosterone system inhibition, anti‐hypertensive treatment and smoking (P < 0.001). This remained significant (P < 0.001) when only including patients on stable renin–angiotensin–aldosterone system inhibition during follow‐up (n = 465). Conclusions Treatment with CSII over 4 years independently reduced HbA1c and UACR compared with MDI. Reduced UACR may be due to less glycaemic variability because the effect of CSII on HbA1c could only partially explain the effect. This needs confirmation in randomized controlled trials.Funding Information
- Steno Diabetes Center
This publication has 20 references indexed in Scilit:
- Assessing glycaemic variability with continuous glucose monitoring system before and after continuous subcutaneous insulin infusion in people with Type 1 diabetesDiabetes Research and Clinical Practice, 2010
- Continuous subcutaneous insulin infusion (CSII) versus multiple insulin injections for type 1 diabetes mellitusEmergencias, 2010
- Continuous subcutaneous insulin infusion is more effective than multiple daily insulin injections in preventing albumin excretion rate increase in Type 1 diabetic patientsDiabetic Medicine, 2009
- Microalbuminuria and the Risk for Early Progressive Renal Function Decline in Type 1 DiabetesJournal of the American Society of Nephrology, 2007
- The Effect of Glucose Variability on the Risk of Microvascular Complications in Type 1 DiabetesDiabetes Care, 2006
- Albuminuria, a Therapeutic Target for Cardiovascular Protection in Type 2 Diabetic Patients With NephropathyCirculation, 2004
- Biochemistry and molecular cell biology of diabetic complicationsNature, 2001
- Predictors of the development of microalbuminuria in patients with Type 1 diabetes mellitus: a seven‐year prospective studyDiabetic Medicine, 1999
- The Effect of Intensive Treatment of Diabetes on the Development and Progression of Long-Term Complications in Insulin-Dependent Diabetes MellitusThe New England Journal of Medicine, 1993
- EFFECT OF TWO YEARS OF STRICT METABOLIC CONTROL ON PROGRESSION OF INCIPIENT NEPHROPATHY IN INSULIN-DEPENDENT DIABETESThe Lancet, 1986